Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.
about
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue diseaseCold hands--strained heart? Advances in the management of Raynaud's phenomenon and pulmonary hypertensionDeveloping pulmonary vasculopathy in systemic sclerosis, detected with non-invasive cardiopulmonary exercise testingPulmonary arterial hypertension: an updateApplication of the DETECT algorithm for detection of risk of pulmonary arterial hypertension in systemic sclerosis: data from a Czech tertiary centre.Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia.Imaging lung disease in systemic sclerosis.Trends in pulmonary hypertension mortality and morbidityPoor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fractionHigh sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center.Therapy for pulmonary arterial hypertension associated with systemic sclerosis.Diagnosis and management of pulmonary hypertension in systemic sclerosis.Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.Submaximal heart and pulmonary evaluation: a novel noninvasive test to identify pulmonary hypertension in patients with systemic sclerosisScleroderma lung diseaseSystemic sclerosis-associated pulmonary arterial hypertensionSaudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseasesEchocardiography may help detect pulmonary vasculopathy in the early stages of pulmonary artery hypertension associated with systemic sclerosis.Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressureEffect of Th17 and Treg axis disorder on outcomes of pulmonary arterial hypertension in connective tissue diseasesAltered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertensionNumerical simulation of blood flow and pressure drop in the pulmonary arterial and venous circulation.Relation of novel echocardiographic measures to invasive hemodynamic assessment in scleroderma-associated pulmonary arterial hypertension.Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung diseaseUnique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registryLung involvement in systemic sclerosis.An official American Thoracic Society Statement: pulmonary hypertension phenotypesPulmonary arterial hypertension associated with systemic sclerosis.Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive dClinical, functional and health-related quality of life correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis: a cross-sectional survey.Connective tissue disease presenting with signs and symptoms of pulmonary hypertension in childrenPerivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage.The right ventricle in scleroderma (2013 Grover Conference Series).Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension.A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonismPulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.Associated pulmonary arterial hypertension in connective tissue diseases.Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testRight ventricular remodeling in idiopathic and scleroderma-associated pulmonary arterial hypertension: two distinct phenotypes.
P2860
Q24681558-C7A919C0-708D-48A6-81F1-F062E5B6F418Q24816970-4011AAE2-D4D7-42B8-B5D8-2360F80B998EQ28744270-F92355E1-A074-4B0D-B167-75F62EF54D09Q30472109-FF322111-D832-4A0F-9700-783E6F00F99CQ30990678-9421942A-8C3D-457C-9FC6-2F7822377B1CQ33636412-D7B63120-6713-4D9B-8C3D-082EFBA49C65Q33754571-1AD5E1EC-21BA-4B8B-B564-49CB9ABCA6C7Q33765394-8CA88FB6-CC93-41D7-B030-862F13C7F7AEQ33788474-C79E8613-8F12-4320-9E55-ACFD3EFD234CQ33801248-BDE7216D-C0EE-428F-9D49-2EA9DE20EE5CQ33805746-7321D1A5-B339-4088-9121-0C77A69515C5Q33832379-1FF65EB6-F7DD-4682-B144-3402793A9EBAQ33834751-333FDF59-C21C-41A8-AF6E-21BF9FD1D906Q33856163-3D29B1FE-C285-4495-9420-7D0D34F6B519Q33919119-F0474663-2558-420D-AC10-9D26F58B6017Q33950086-E4B9E78E-FA36-41FD-981E-7C070857F1E3Q33965825-030D4036-4C8E-49F7-85B2-7DCA05DFB29AQ34013946-37E44FE7-FDEF-4B0D-9498-733EB2121BA8Q34143652-6F864867-4C76-4E21-8404-EECEAA0833ECQ34151353-CBBC7404-6799-4CD9-B8E4-75957B5D4129Q34250971-7A7331F4-7A80-49BD-B942-DA6878940898Q34280409-14535771-ED07-4DBD-B1AA-FE249C9DC521Q34378873-ECB2508A-1BDF-43DD-8B24-98D6FDF104BEQ34425493-E619634C-1726-4F49-879B-6F9993953923Q34609902-6AD3D3C2-E2F5-4AB8-BA5D-21149F244F0FQ34732817-CF27F981-F1C5-443A-949E-01FA6F4CF2CAQ34919733-5A7EB65C-5807-4E45-9BD8-ED9006AE2833Q35002423-256A8200-46E5-4A9B-980F-AF0CC2A44401Q35093008-D7B61DAC-AEF9-4C71-A301-53DF8E885A0EQ35109082-3104E4FC-5528-4218-B95D-2A3C7B39C24EQ35125574-600997E9-7726-42A6-8E3E-262E06BDFF3AQ35173533-1B75BF0E-6C21-49B2-A0A9-8ACB25B359ABQ35517421-FACE730A-439D-4DD2-A7D8-EDF83DF144EAQ35537991-5FD93187-5724-45CD-A03F-A8A8B9280F8FQ35554571-E04DAC95-8C2C-44A2-93B7-044FF9699CDFQ35591616-A992A525-51D4-4CF0-9388-2FF276AC64C2Q35617799-508FEB6B-BF48-4AE2-8129-745B09ED7677Q35637949-EAF6F6B6-333B-46B8-BF35-058F973FF806Q35638700-0AC2EE10-1655-4D17-8177-7C8A13D9EB09Q35665758-C0D304D5-8855-436D-A5D0-DE4218AD3F44
P2860
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Prevalence and outcome in syst ...... cation of a registry approach.
@ast
Prevalence and outcome in syst ...... cation of a registry approach.
@en
type
label
Prevalence and outcome in syst ...... cation of a registry approach.
@ast
Prevalence and outcome in syst ...... cation of a registry approach.
@en
prefLabel
Prevalence and outcome in syst ...... cation of a registry approach.
@ast
Prevalence and outcome in syst ...... cation of a registry approach.
@en
P2093
P2860
P356
P1476
Prevalence and outcome in syst ...... cation of a registry approach.
@en
P2093
Coghlan JG
Mukerjee D
St George D
P2860
P304
P356
10.1136/ARD.62.11.1088
P407
P577
2003-11-01T00:00:00Z